[Hemodynamic effects of a new alpha-1 antagonist, AR-C 239 administrated in intravenous bolus, in patients with cardiac insufficiency].

Abstract

A new specific alpha-1 antagonist was studied in 16 patients with left ventricular failure. In Group I (8 patients) the drug was given as a 40 micrograms/kg intravenous bolus, and in Group II (8 patients) at the dose of 80 micrograms/kg. A thermodilution Swan-Ganz catheter, a Millar microtransducer introduced via the femoral artery were relayed to a SYSCOMORAM system to record the systemic artery pressures (SAP), pulmonary artery pressures (PAP), left ventricular pressures, and to calculate cardiac output and systemic and pulmonary arterial resistances (SAR, PAR) over a 30 minute period. In Group I (40 micrograms/kg), administration of AR-C 239 led to a significant decrease in PAP and SAP (-24 +/- 17 p. 100, p less than 0.02) with a fall in time-tension index (-20 +/- 19 p. 100, p less than 0.05) and a significant increase in LV stroke volume (+23 +/- 12 p. 100, p less than 0.01). At 80 micrograms/kg there was also a fall in LV filling pressures (-29 +/- 25 p. 100, p less than 0.05) and PAP (-38 +/- 28 p. 100, p less than 0.02) and an improvement in LV compliance (Gaaschisk -43 +/- 19 p. 100, p less than 0.01). These results show that AR-C 239 is a powerful vasodilator without secondary beta mimetic effects or influence on LV contractility; it may provide an effective means of treating cardiac failure.

• Authors: J P Colle, J Hilaire, J Ohayon, P Besse
• Journal: Archives des maladies du coeur et des vaisseaux (Arch Mal Coeur Vaiss) Vol. 80 Issue 1 Pg. 84-91 (Jan 1987) ISSN: 0003-9683 [Print] France
• Vernacular Title: Effets hémodynamiques d'une nouvelle molécule alpha 1 antagoniste, l'AR-C 239 administré en bolus intraveineux, chez les patients en insuffisance cardiaque.
• PMID: 3107496 (Publication Type: Journal Article)

Chemical References

• Isoquinolines
• Piperazines
• Vasodilator Agents
• AR-C239

Topics

• Adult
• Aged
• Dose-Response Relationship, Drug
• Female
• Heart Failure (drug therapy, physiopathology)
• Hemodynamics (drug effects)
• Humans
• Injections, Intravenous
• Isoquinolines (pharmacology, therapeutic use)
• Male
• Middle Aged
• Piperazines
• Time Factors
• Vasodilator Agents (pharmacology)